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Abstract: Background. In accord with the cancer stem cell
(CSC) theory, only a small subset of cancer cells are capable
of forming tumors. We previously reported that CD44 isolates
tumorigenic cells from head and neck squamous cell cancer
(HNSCC). Recent studies indicate that aldehyde dehydrogen-
ase (ALDH) activity may represent a more specific marker of
CSCs.
Methods. Six primary HNSCCs were collected. Cells with
high and low ALDH activity (ALDHhigh/ALDHlow) were isolated.
ALDHhigh and ALDHlow populations were implanted into NOD/
SCID mice and monitored for tumor development.
Results. ALDHhigh cells represented a small percentage of
the tumor cells (1% to 7.8%). ALDHhigh cells formed tumors
from as few as 500 cells in 24/45 implantations, whereas only
3/37 implantations of ALDHlow cells formed tumors.
Conclusions. ALDHhigh cells comprise a subpopulation
cells in HNSCCs that are tumorigenic and capable of produc-
ing tumors at very low numbers. This finding indicates that
ALDH activity on its own is a highly selective marker for CSCs
in HNSCC. VC 2010 Wiley Periodicals, Inc. Head Neck 32:
1195–1201, 2010
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Head and neck cancer is a common malignancy
that affects approximately 40,000 new patients
in the United States each year.1 Despite advan-
ces in therapy that have improved quality of
life, survival rates have remained static for
many years. Mortality from this disease remains
high because of the development of distant me-
tastasis and the emergence of treatment-resist-
ant local and regional recurrences. To develop
more effective therapies for head and neck squa-
mous cell cancer (HNSCC), it is essential that
we gain a deeper understanding of the biology
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of this disease and the cells that are responsible
for recurrent and persistent cancer.
The cancer stem cell (CSC) theory of carcino-
genesis postulates that tissue stem cells or pro-
genitor cells are a target for genetic changes that
lead to malignant transformation. Based on their
similarity to normal stem cells, CSCs are also
likely to be more resistant to therapy and may be
responsible for tumor persistence and recur-
rence. Evidence has been accumulating that sup-
ports the validity of this theory in a number of
malignant diseases.2–8 Epithelial cancers, includ-
ing HNSCCs, contain heterogeneous populations
of cells, some of which are tumorigenic and many
others that are not. Accumulated evidence indi-
cates that CSCs retain phenotypic features of
their cell of origin, irrespective of whether that is
a stem cell or an early progenitor cell.9,10 Stem
cell markers or molecular processes that are also
expressed on CSCs should provide the means to
identify and study CSCs. Thus, conserved stem
cell molecular pathways may possibly be used in
the search for CSCs.
In recent studies in breast and central nerv-
ous system cancers, tumorigenic subpopulations
of ‘‘CSCs’’ have been isolated based on expression
of cell surface markers.11–16 Using a modification
of a method used to identify CSCs in breast can-
cer we isolated a subpopulation of HNSCC cells
marked by the cell surface marker CD44 (CD44-
positive cells [CD44þ]) that produce tumors in
the NOD/SCID mouse model.12,17 In contrast,
even 10-fold higher numbers of CD44-negative
(CD44) tumor cells were unable to form
tumors. Although this was the first demonstra-
tion of CSCs in HNSCC, the high percentage of
HNSCCs found to be CD44þ and the number of
such cells necessary (5  103) to develop a tumor
suggested that, although the CD44þ cell popula-
tion contained CSCs, it was unlikely to be a pure
population of CSCs.
Aldehyde dehydrogenase (ALDH) expression
has been suggested as a potential functional
marker for stem cells and CSCs. ALDH, which
detoxifies intracellular aldehydes through oxida-
tion, may have a role in the differentiation of
stem cells through the oxidation of retinoic
acid.18–20 High ALDH activity has been used to
isolate normal hematopoietic and central nerv-
ous system stem cells.21–24 ALDH activity is
also found in subsets of multiple myeloma and
acute myeloid leukemia.24,25 Wicha et al26 used
ALDH activity to isolate breast CSCs. ALDH 1
expression has recently been reported to be a
putative marker for CSCs in HNSCC and colon
cancer.27,28 These findings indicate that ALDH
expression may be an important new marker for
the isolation of CSCs. In this study we investi-
gated the ALDH active population of HNSCC
cells for tumorigenic activity.
MATERIALS AND METHODS
Approvals for the collection of cancer specimens
and for use of the animal model were obtained
through the appropriate review boards. The Uni-
versity of Michigan’s Guide for the Care and Use
of Laboratory Animals was followed. Samples of
HNSCC cancer were obtained from subjects
undergoing surgical resection or biopsy of their
tumor. Specimens were immediately transported
to the laboratory in Dulbecco’s modified Eagle’s
medium (DMEM; GIBCO Media/Invitrogen
Corp., Carlsbad, CA) containing 10% fetal bovine
serum (FBS; Sigma–Aldrich, St. Louis, MO) on
ice. Single-cell suspensions were created.
Specimens were cut into small fragments
with sterile scissors and minced with a sterile
scalpel, rinsed with Hanks’ balanced salt solu-
tion (HBSS; Invitrogen) containing 2% heat-inac-
tivated calf serum (HICS; Invitrogen), and
centrifuged for 5 minutes at 1000 rpm. The
resulting tissue specimen was placed in a solu-
tion of DMEM F-12 containing 300 U/mL collage-
nase and 100 U/mL hyaluronidase (STEMCELL
Technologies, Vancouver, BC, Canada). The mix-
ture was incubated at 37C mixing to dissociate
cells. The digestion was arrested with the addi-
tion of FBS and the cells were filtered through a
40-lm nylon sieve. The cells were washed twice
with HBSS/2% HICS and stained for flow cytom-
etry as described in the following text.
ALDH activity was identified in the cancer
cells using the ALDEFLUOR substrate in accord
with the manufacturer’s protocol (StemCo Bio-
medical, Durham, NC). Specimens that were an-
alyzed for ALDH activity were counterstained
with anti-CD44 (allophycocyanin [APC] conju-
gated; BD Pharmingen, San Diego, CA) at the
appropriate dilution. Cells of other lineages
were identified and removed using markers
anti-CD2, CD3, CD10, CD16, and CD18
(CyChrome [Cy] conjugated; BD Pharmingen)
that are not expressed on the tumor cells. Non-
viable cells were eliminated using 40,6-diami-
dino-2-phenylindole (DAPI; BD Pharmingen).
During flow cytometry analysis, other lineage
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cells and the DAPI-stained dead cells were elim-
inated by gating. The specific flow gates for
ALDH-positive cells were set using a control
sample of the isolated tumor cells in which
ALDH activity was inhibited with diethylamino-
benzaldehyde (DEAB). Subsequent flow cytome-
try runs were used to identify populations of
cells with high aldehyde dehydrogenase activity
(ALDHhigh) and those that express the surface
marker CD44 (CD44þ), whereas measurements
of cell numbers were used to identify the per-
centage of each population present: ALDHhigh,
ALDHlow, CD44þ, and CD44. Overlap between
these populations was assessed to identify popu-
lations of cells with the characteristics CD44þ
ALDHhigh, CD44þ ALDHlow, CD44- ALDHhigh,
and CD44 ALDHlow in HNSCC.
HNSCC subpopulations of interest were col-
lected based on their ALDH expression. Subpo-
pulations of ALDHhigh and ALDHlow cells were
injected subcutaneously into NOD/SCID mice
and evaluated for their tumorigenic potential.
When sufficient numbers were available, the
cells were serially diluted prior to injection. The
cells were mixed with Matrigel Basement Mem-
brane Matrix (BD Pharmingen) solution to form
a final volume of 200 lL. Injection sites were
sealed with a liquid skin adhesive. The animals
were assessed for tumor growth.
The tumorgenicity of the injected cell popula-
tions was evaluated by evidence of tumor
growth in NOD/SCID mice and by histology.
When the number of cells allowed for serial
dilutions to be injected, we determined the mini-
mum number of cells required for each popula-
tion to produce a tumor in the NOD/SCID
mouse. The resultant tumors were assessed by
flow cytometric and histologic analysis for tumor
heterogeneity and proportion of cells with
ALDH activity.
RESULTS
Six primary tumors were collected from subjects
with HNSCC. Two tumors originated in the oral
cavity (floor of mouth, tongue), 3 originated in
the oropharynx (2 in the tonsil, 1 base of tongue),
and 1 originated in the larynx. The subjects
ranged in age from 45 to 74 years old. There
were 3 moderately differentiated, 2 poorly differ-
entiated, and 1 well-differentiated tumor (Table
1). Although most of the tumor samples were
small, when sufficient numbers of cells were
available costained flow cytometry sorts and
injections of serially diluted cells were performed.
HNSCC can be separated into 2 subpopula-
tions using the ALDEFLUOR substrate to




Sex Site Classification Differentiation
HN72 74/M Tonsil T2N0M0 Well
HN76 71/F Floor of mouth T3N2cM0 Poor
HN78 67/M Oral tongue T2N2cM0 Moderate
HN79 45/F Tonsil T2N1M0 Moderate
HN80 44/M Larynx T3N0M0 Moderate
HN84 59/M Tongue base T4N0M0 Poor
Abbreviations: M, male; F, female.
FIGURE 1. Head and neck squamous cell carcinoma (HNSCC) cells that have high levels of aldehyde dehydrogenase (ALDH) expres-
sion also express CD44 at high levels. (A) HN79 cells sorted for ALDH expression. P6 represents cells with high levels of ALDH
expression (ALDHhigh). (B) Only HN79 cells with elevated ALDH levels (P6) have been sorted for CD44 expression. The cells in P10
represent the population of cells with high ALDH expression that also express CD44. Approximately 70% of the ALDH high cells are
also CD44þ.
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determine ALDH activity and flow cytometry to
sort and collect the cells. As expected, the ma-
jority of HNSCC cells had low ALDH activity. In
these tumors, the proportion of ALDHhigh cells
had a mean of 3.5  2.8% (1.0% to 7.8%).
The ALDHhigh subpopulation overlaps signifi-
cantly with the CD44þ population of cells.
When the ALDHhigh population was sorted for
CD44, the majority of cells also expressed CD44,
50.6% to 74.4% (Figure 1 and Table 2). Con-
versely, when CD44þ cells were sorted for
ALDH activity, only 9.8% to 23.6% of the
CD44þ cells had high ALDH activity, indicating
that a large proportion of ALDHhigh cells are
CD44þ, but a much smaller proportion of
CD44þ cells are ALDHhigh.
ALDHhigh HNSCC cells are highly tumori-
genic compared with ALDHlow cells (Table 3).
HNSCC cells with high ALDH activity produced
tumors in the NOD/SCID mouse model in 24/45
injections (53%), whereas HNSCC cells with low
ALDH activity resulted in tumors in only 3/37
injections (p < .00001, chi-square test). Tumors
developed in 7/15 (47%) mice injected with as
few as 50 to 100 ALDHhigh HNSCC cells,
whereas no tumors occurred in 0/14 injections of
the same number of ALDHlow cells.
ALDHhigh cells produce tumors that have a
histology similar to that of the original tumor
(see Figure 2). The ALDHhigh cells can be pas-
saged in the mouse model and reproduce the
original tumor heterogeneity for ALDH activ-
ity—that is, the proportion of cells that are
ALDHhigh is similar to the proportion in the
original tumor (see Figure 3).
DISCUSSION
The identification of highly tumorigenic subpo-
pulations of cells—the CSCs—in solid tumors
has significant implications regarding cancer
biology, response to therapy, and the develop-
ment of new cancer treatments. Therapies based
on tumor regression may produce treatments
effective against the majority of more differenti-
ated cancer cells while sparing the CSC subpo-
pulation.8 The development of more effective
cancer therapeutics will require the CSCs to be
selectively targeted and eliminated. For this
strategy to be successful, the CSC cells must be
reliably identified and isolated so their charac-
teristics can be studied.
CD44 is a cell surface marker that identifies
a subpopulation of cancer cells from HNSCCs
that are highly tumorigenic. However, the CD44
subpopulation of HNSCCs likely contains both
non-CSCs and CSCs as shown by the need to
Table 3. Number of tumors resulting from implantations of ALSHhigh and ALDHlow cells for each HNSCC specimen.
Sample Population
No. of cells injected
5000þ 1001–5000 501–1000 101–500 50–100
HN72 ALDHhigh 1/2 0/1 1/1 2/3
ALDHlow 0/1 0/2 0/4
HN76 ALDHhigh 1/3 2/2 0/2
ALDHlow 1/2
HN78 ALDHhigh 3/4 2/4 2/4
ALDHlow 0/4 1/4 0/4
HN79 ALDHhigh 1/1 1/1 1/1 2/4
ALDHlow 0/1 0/2 0/4
HN80 ALDHhigh 0/2 1/2 2/4
ALDHlow 0/3 0/2
HN84 ALDHhigh 1/2 1/2
ALDHlow 1/2 0/2
Abbreviations: ALDH, aldehyde dehydogenase; HNSCC, head and neck squamous cell cancer.
Table 2. Percentage of ALDHhigh cells in the HNSCC
specimens, percentage of CD44þ cells that are ALDHhigh,










HN72 1.0 70.2 23.60
HN76 1.8 74.4 16.49
HN78 1.3 50.6 13.40
HN79 6.2 72.9 N/A
HN80 7.8 69.9 N/A
HN84 2.6 N/A 9.86
Abbreviations: ALDH, aldehyde dehydogenase; HNSCC, head and
neck squamous cell cancer, N/A, not applicable.
Note: Not all combinations are reported because of limitations related
to cell numbers available for analysis.
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inject in the order of 5  103 cells to produce a
tumor in the animal model.17 In other cancers,
combinations of cell surface markers have been
used successfully to isolate CSCs, and smaller
numbers of the isolated cells have been shown
to produce tumors in an animal model, suggest-
ing this methodology is capable of isolating the
CSCs more selectively. These findings indicated
FIGURE 3. ALDHhigh cells re-create the original tumor heterogeneity for ALDH expression and maintain the distribution of ALDH in
cancer cells passaged in the animal model. (A) Primary HN84 cancer cells inhibited with diethylamino-benzaldehyde (DEAB). (B) Pri-
mary HN84 cancer cells sorted for ALDH expression: 11.1% of the cancer cells are ALDHhigh. (C) Cancer cells derived from tumors
grown in the animal model (passage 1) inhibited with DEAB. (D) Cancer cells sorted for ALDH expression from tumor grown in the ani-
mal model from HN84 ALDHhigh exhibit the same heterogeneity for ALDH expression as the original tumor.
FIGURE 2. ALDHhigh cells reproduce tumors that are histologically similar to the original tumor. (A) HN84 primary tumor (original mag-
nification, 20). (B) HN84 tumor resultant from ALDHhigh injection (original magnification, 20). [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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a need to identify a more selective single marker
or combination of markers for CSCs in
HNSCCs.
Wicha et al26 recently demonstrated that
ALDH expression can be used to identify breast
CSCs and that injections of small numbers of
these cells produce tumors in an animal model.
Interestingly, the normal breast stem/progenitor
cells also have high expression of ALDH,
strongly supporting the concept that stem and
progenitor cells are the targets of malignant
transformation in breast cancer.26
We have shown here that ALDH expression
isolates a subpopulation of cancer cells from
HNSCCs that are highly tumorigenic. The
ALDH-positive cells are able to produce tumors
at a 10-fold reduction over that which was possi-
ble with CD44þ cells alone.17 The tumors grown
from ALDHhigh cells re-create the original tumor
heterogeneity and histology, and the ALDHhigh
cells can be passaged in the animal model, ful-
filling the requirements for CSC phenotype.
These data along with the recent report by
Chen et al27 strongly support the use of ALDH
expression as a method to select CSCs in
HNSCC.
As expected, the ALDH subpopulation of
HNSCC cells mainly comprise a small subpopu-
lation of the CD44þ cells, suggesting ALDH
expression isolates a subset of CD44þ cells that
contain the actual tumorigenic CSCs (see Figure
4). Thus we conclude that the tumorigenic cells
have both phenotypic markers. The explanation
as to why CD44 and ALDH are expressed by
the stem cell population is not known, although
one could speculate that the ability to oxidize
retinoic acid, a proposed function of ALDH, is a
requirement for stem cell activity. It is also not
certain that both markers are always expressed
on the tumorigenic stem cells because there
appears to be a small fraction of ALDH-positive
cells that are CD44. However, the limited
number of cells precluded a separate selection of
these cells for testing, and our prior experi-
ments had shown that even large numbers of
CD44-negative cells are not tumorigenic. No
doubt there are other phenotypic markers that
are expressed by CSCs. For example, in breast
cancer, CD24 is also a stem cell marker. In
HNSCC, this does not appear to be the case;
thus there seem to be tissue-specific stem cell
markers as well as general stem cell markers.
ALDH expression may represent a CSC that is
generally applicable to all CSCs, although this
remains to be proven.
The small numbers of CSCs obtained from
HNSCC limit the critical experiments that
must be carried out to understand the role of
these cells in cancer persistence, recurrence,
and resistance to therapy. Repeated recultiva-
tion in the NOD/SCID mouse or in vitro culture
methods would allow for repeated experiments,
and our future work will target these
mechanisms.
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